{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T02:42:34Z","timestamp":1768444954571,"version":"3.49.0"},"reference-count":40,"publisher":"BMJ","issue":"4","funder":[{"DOI":"10.13039\/100005639","name":"Fidelity Foundation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100005639","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Sex Reprod Health"],"accepted":{"date-parts":[[2021,11,3]]},"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1136\/bmjsrh-2021-201321","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T13:21:07Z","timestamp":1638537667000},"page":"238-242","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["Making the case for advance provision of mifepristone and misoprostol for abortion in the United States"],"prefix":"10.1136","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8174-3863","authenticated-orcid":false,"given":"Katherine","family":"Ehrenreich","sequence":"first","affiliation":[{"name":"Advancing New Standards In Reproductive Health (ANSIRH), Bixby Center for Global Reproductive Health, Department of Obstetrics, Gynecology & Reproductive Sciences, University of California San Francisco, Oakland, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3904-3177","authenticated-orcid":false,"given":"M Antonia","family":"Biggs","sequence":"additional","affiliation":[{"name":"Advancing New Standards In Reproductive Health (ANSIRH), Bixby Center for Global Reproductive Health, Department of Obstetrics, Gynecology & Reproductive Sciences, University of California San Francisco, Oakland, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3221-9368","authenticated-orcid":false,"given":"Daniel","family":"Grossman","sequence":"additional","affiliation":[{"name":"Advancing New Standards In Reproductive Health (ANSIRH), Bixby Center for Global Reproductive Health, Department of Obstetrics, Gynecology & Reproductive Sciences, University of California San Francisco, Oakland, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,12,3]]},"reference":[{"key":"2025090511365146000_48.4.238.1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000000603"},{"key":"2025090511365146000_48.4.238.2","unstructured":"US Food and Drug Administration . Postmarket drug safety information for patients and providers - Mifeprex (mifepristone) information, 2020. Available: https:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm111323.htm [Accessed 19 Aug 2021]."},{"key":"2025090511365146000_48.4.238.3","unstructured":"US Food and Drug Administration . Medication guide highlights of prescribing information, 2016. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/020687s020lbl.pdf [Accessed 19 Aug 2021]."},{"key":"2025090511365146000_48.4.238.4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.contraception.2021.04.025","article-title":"The mifepristone REMS: a needless and unlawful barrier to care","volume":"104","author":"Kaye","year":"2021","journal-title":"Contraception"},{"key":"2025090511365146000_48.4.238.5","unstructured":"Liptak A . Supreme court urged to reject Mississippi\u2019s attack on Roe v. Wade. New York Times, 2021. Available: https:\/\/www.nytimes.com\/2021\/09\/13\/us\/politics\/mississippi-abortion-supreme-court.html [Accessed 5 Oct 2021]."},{"key":"2025090511365146000_48.4.238.6","unstructured":"Texas Eighty-Seventh Legislature . Texas Senate bill 8, 2021. Available: https:\/\/legiscan.com\/TX\/text\/SB8\/id\/2395961 [Accessed 5 Oct 2021]."},{"key":"2025090511365146000_48.4.238.7","unstructured":"US Food and Drug Administration . Letter to the American College of Obstetricians and Gynecologists and Society for Maternal-Fetal Medicine - Janet Woodcock, Acting Commissioner of Food and Drugs, 2021. Available: https:\/\/www.aclu.org\/sites\/default\/files\/field_document\/fda_acting_commissioner_letter_to_acog_april_12_2021.pdf [Accessed 19 Aug 2021]."},{"key":"2025090511365146000_48.4.238.8","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/1471-0528.16668","article-title":"Effectiveness, safety and acceptability of no-test medical abortion (termination of pregnancy) provided via telemedicine: a national cohort study","volume":"128","author":"Aiken","year":"2021","journal-title":"BJOG"},{"key":"2025090511365146000_48.4.238.9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.contraception.2020.08.004","article-title":"Medication abortion up to 70 days of gestation","volume":"102","year":"2020","journal-title":"Contraception"},{"key":"2025090511365146000_48.4.238.10","unstructured":"Guilbert E , Costescu D , Wagner M-S . Canadian protocol for the provision of medical abortion via telemedicine. health Canada, 2019. Available: https:\/\/sogc.org\/common\/uploaded%20files\/canadian%20protocol%20for%20the%20provision%20of%20ma%20via%20telemedicine.pdf [Accessed 19 Aug 2021]."},{"key":"2025090511365146000_48.4.238.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2020.04.005"},{"key":"2025090511365146000_48.4.238.12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.contraception.2019.05.013","article-title":"TelAbortion: evaluation of a direct to patient telemedicine abortion service in the United States","volume":"100","author":"Raymond","year":"2019","journal-title":"Contraception"},{"key":"2025090511365146000_48.4.238.13","doi-asserted-by":"publisher","DOI":"10.1111\/ajo.12800"},{"key":"2025090511365146000_48.4.238.14","unstructured":"American College of Obstetricians and Gynecologists (ACOG) . ACOG statement on court\u2019s order lifting burdensome FDA restriction, 2020. Available: https:\/\/www.acog.org\/news\/news-releases\/2020\/07\/acog-statement-on-courts-order-lifting-burdensome-fda-restriction [Accessed 19 Aug 2021]."},{"key":"2025090511365146000_48.4.238.15","unstructured":"ClinicalTrials.gov . Mail order mifepristone study, 2020. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03913104 [Accessed 19 Aug 2021]."},{"key":"2025090511365146000_48.4.238.16","unstructured":"ClinicalTrials.gov . Medication abortion via pharmacy dispensing, 2020. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03320057 [Accessed 19 Aug 2021]."},{"key":"2025090511365146000_48.4.238.17","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/AOG.0000000000004312","article-title":"Medication abortion with pharmacist dispensing of mifepristone","volume":"137","author":"Grossman","year":"2021","journal-title":"Obstet Gynecol"},{"key":"2025090511365146000_48.4.238.18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1049-3867(97)00117-5","article-title":"Experience and acceptability of medical abortion with mifepristone and misoprostol among U.S. women","volume":"7","author":"Beckman","year":"1997","journal-title":"Womens Health Issues"},{"key":"2025090511365146000_48.4.238.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200003303421307"},{"key":"2025090511365146000_48.4.238.20","unstructured":"Jones RK , Witwer E , Jerman J . Abortion incidence and service availability in the United States, 2017. Guttmacher Institute, 2019."},{"key":"2025090511365146000_48.4.238.21","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.10.084046"},{"key":"2025090511365146000_48.4.238.22","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2012.301097"},{"key":"2025090511365146000_48.4.238.23","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/AOG.0000000000003183","article-title":"Change in second-trimester abortion after implementation of a restrictive state law","volume":"133","author":"White","year":"2019","journal-title":"Obstet Gynecol"},{"key":"2025090511365146000_48.4.238.24","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/jama.2020.24096","article-title":"Changes in abortion in Texas following an executive order ban during the coronavirus pandemic","volume":"325","author":"White","year":"2021","journal-title":"JAMA"},{"key":"2025090511365146000_48.4.238.25","doi-asserted-by":"crossref","DOI":"10.2196\/jmir.9717","article-title":"Identifying national availability of abortion care and distance from major US cities: systematic online search","volume":"20","author":"Cartwright","year":"2018","journal-title":"J Med Internet Res"},{"key":"2025090511365146000_48.4.238.26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165048","article-title":"Women's experience obtaining abortion care in Texas after implementation of restrictive abortion laws: a qualitative study","volume":"11","author":"Baum","year":"2016","journal-title":"PLoS One"},{"key":"2025090511365146000_48.4.238.27","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.contraception.2015.12.017","article-title":"Women's experiences seeking abortion care shortly after the closure of clinics due to a restrictive law in Texas","volume":"93","author":"Fuentes","year":"2016","journal-title":"Contraception"},{"key":"2025090511365146000_48.4.238.28","unstructured":"White K , Sierra G , Dixon L . Texas Senate bill 8: medical and legal implications. Texas policy evaluation project, 2021. Available: https:\/\/liberalarts.utexas.edu\/txpep\/research-briefs\/senate-bill-8.php [Accessed 5 Oct 2021]."},{"key":"2025090511365146000_48.4.238.29","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2105\/AJPH.2021.306284","article-title":"Disruptions to abortion care in Louisiana during early months of the COVID-19 pandemic","volume":"111","author":"Roberts","year":"2021","journal-title":"Am J Public Health"},{"key":"2025090511365146000_48.4.238.30","unstructured":"Jones RK , Jerman J . Time to appointment and delays in accessing care among U.S. abortion patients. Guttmacher Institute, 2016. Available: https:\/\/www.guttmacher.org\/report\/delays-in-accessing-care-among-us-abortion-patients [Accessed 19 Aug 2021]."},{"key":"2025090511365146000_48.4.238.31","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2013.301378"},{"key":"2025090511365146000_48.4.238.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2006.04.010"},{"key":"2025090511365146000_48.4.238.33","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.contraception.2020.12.010","article-title":"Abortion method preference among people presenting for abortion care","volume":"103","author":"Wingo","year":"2021","journal-title":"Contraception"},{"key":"2025090511365146000_48.4.238.34","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.contraception.2020.05.012","article-title":"A repeat dose of misoprostol 800 mcg following mifepristone for outpatient medical abortion at 64-70 and 71-77 days of gestation: a retrospective chart review","volume":"102","author":"Dzuba","year":"2020","journal-title":"Contraception"},{"key":"2025090511365146000_48.4.238.35","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.contraception.2018.10.007","article-title":"Support for and interest in alternative models of medication abortion provision among a national probability sample of U.S. women","volume":"99","author":"Biggs","year":"2019","journal-title":"Contraception"},{"key":"2025090511365146000_48.4.238.36","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.contraception.2020.08.014","article-title":"Exploring potential interest in missed period pills in two US states","volume":"102","author":"Sheldon","year":"2020","journal-title":"Contraception"},{"key":"2025090511365146000_48.4.238.37","doi-asserted-by":"publisher","DOI":"10.1016\/s0010-7824(01)00300-6"},{"key":"2025090511365146000_48.4.238.38","unstructured":"US food and drug administration center for drug evaluation and research. Application number: 21-045\/S011, 2006. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2006\/021045s011_Plan_B__MedR.pdf [Accessed 19 Aug 2021]."},{"key":"2025090511365146000_48.4.238.39","doi-asserted-by":"crossref","DOI":"10.1016\/j.contraception.2020.03.020","article-title":"Differences in abortion service-delivery in clinics by state policy context in 2017","volume":"101","author":"Witwer","year":"2020","journal-title":"Contraception"},{"key":"2025090511365146000_48.4.238.40","doi-asserted-by":"publisher","DOI":"10.1363\/psrh.12024"}],"container-title":["BMJ Sexual & Reproductive Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjsrh-2021-201321","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T18:56:18Z","timestamp":1757098578000},"score":1,"resource":{"primary":{"URL":"https:\/\/jfprhc.bmj.com\/lookup\/doi\/10.1136\/bmjsrh-2021-201321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,3]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,10,12]]},"published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1136\/bmjsrh-2021-201321"],"URL":"https:\/\/doi.org\/10.1136\/bmjsrh-2021-201321","relation":{},"ISSN":["2515-1991","2515-2009"],"issn-type":[{"value":"2515-1991","type":"print"},{"value":"2515-2009","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,3]]}}}